Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.
Despite new therapeutic options and treatment strategies, anemia still remains one of the major complications of chronic kidney disease (CKD), especially in patients undergoing chronic hemodialysis for end-stage renal disease. Successful management of anemia is a central part of patient care that may improve clinical outcomes. Although the National Kidney Foundation Dialysis Outcomes Quality Initiative (NKF-DOQI) working group reformulated its recommendations by stating that the hemoglobin target in patients receiving erythropoiesis stimulatory agents (ESA) should generally be 11-12 g/dl, this target value can not be achieved in many of them, despite treatment with high doses of ESA. The aim of the present review is to provide an update of the recent literature on causes and possible management of ESA-resistant anemia in CKD patients.
Kanbay
Mehmet
M
Department of Medicine, Section of Nephrology, Fatih University School of Medicine, Ankara, Turkey. drkanbay@yahoo.com
Perazella
Mark A
MA
Kasapoglu
Benan
B
Koroglu
Mustafa
M
Covic
Adrian
A
D000740:Anemia / Q000188:drug therapy / Q000209:etiology*; D018798:Anemia, Iron-Deficiency / Q000188:drug therapy / Q000209:etiology; D004351:Drug Resistance / Q000502:physiology; D004920:Erythropoiesis; D004921:Erythropoietin / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use*; D006801:Humans; D007249:Inflammation / Q000150:complications; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D010349:Patient Compliance; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin